Primary failure of bortezomib in newly diagnosed multiple myeloma – understanding the magnitude, predictors, and significance-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Primary failure of bortezomib in newly diagnosed multiple myeloma – understanding the magnitude, predictors, and significance

Published:2016-01-04 Issue:6 Volume:57 Page:1382-1388
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Cohen Yael C.,Joffe Erel,Benyamini Noam,Dimopoulos Meletios A.,Terpos Evangelos,Trestman Svetlana,Held-Kuznetsov Viki,Avivi Irit,Kastritis Efstathios

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2015.1121258

Reference24 articles.

1. Proteasome inhibitors in multiple myeloma: 10 years later

2. Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial

3. Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

4. Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response adaptive salvage treatment with daratumumab–lenalidomide–dexamethasone for newly diagnosed transplant‐eligible multiple myeloma patients failing front‐line bortezomib‐based induction therapy—ALLG MM21;British Journal of Haematology;2024-06-08

2. Development and validation of a machine learning-based postoperative prognostic model for plasma cell neoplasia with spinal lesions as initial clinical manifestations: a single-center cohort study;European Spine Journal;2024-04-07

3. Effect of CYP2C19 polymorphism on response to bortezomib-based therapy in multiple myeloma patients;The American Journal of the Medical Sciences;2024-03

4. Microarray-Based CD38 Peptide Probe Screening for Multiple Myeloma Imaging;Molecular Pharmaceutics;2023-12-14

5. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy;Blood Advances;2023-08-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3